Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies

Please visit answersincme.com/VET860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the use of adjuvant chemotherapy for patients with early-stage non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for adjuvant immunotherapy in patients with early-stage non–small-cell lung cancer (NSCLC) following surgery and chemotherapy; Review the clinical profiles of approved and emerging adjuvant immunotherapy regimens in early-stage NSCLC; and Outline factors that optimize integration of adjuvant immunotherapy regimens for early-stage NSCLC into clinical practice.